1887

Abstract

The role of the third variable domain (V3) of gp120 in the neutralization of primary and T-cell line adapted (TCLA) strains of human immunodeficiency virus type 1 (HIV-1) by serum from HIV-1-infected individuals was investigated. A primary virus isolate, M2424/4, when adapted to H9 cells, was more sensitive to neutralization on MT2 cells than the same stock passaged in PBMC. Neutralization of the PBMC-passaged stock by V3-specific MAbs was abrogated by addition of V3 (MN) peptide. However, exogenous V3 (MN) peptide failed to reduce the neutralization of this isolate on PBMC, or MT2 cells, by high titre anti-HIV-1 polyclonal human sera in contrast to the extensive reduction of neutralization by the same sera on MT2 cells using the prototype MN strain (4- to ≥ 24-fold) and the TCLA M2424/H9 isolate (2- to 8-fold). These results indicate that the neutralization of primary virus isolates by serum from HIV-1-infected individuals is not significantly mediated by V3- specific antibodies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-79-1-77
1998-01-01
2022-11-27
Loading full text...

Full text loading...

/deliver/fulltext/jgv/79/1/9460926.html?itemId=/content/journal/jgv/10.1099/0022-1317-79-1-77&mimeType=html&fmt=ahah

References

  1. Bou Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P., Norcross M. A. 1994; Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. Journal of Virology 68:6006–6013
    [Google Scholar]
  2. Boyd M. T., Simpson G. R., Cann A. J., Johnson M. A., Weiss R. A. 1993; A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. Journal of Virology 67:3649–3652
    [Google Scholar]
  3. Cheingsong-Popov R., Callow D., Beddows S., Shaunak S., Wasi C., Kaleebu P., Gilks C., Petrascu I. V., Garaev M. M., Watts D. M., Constantine N. T., Weber J. N. 1992; Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. Journal of Infectious Diseases 165:256–261
    [Google Scholar]
  4. Cohen J. 1993; Jitters jeopardize AIDS vaccine trials. Science 262:980
    [Google Scholar]
  5. Conley A. J., Gorny M. K., Kessler J. A., Boots L. J., Ossorio Castro M., Koenig S., Lineberger D. W., Emini E. A., Williams C., Zolla Pazner S. 1994; Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. Journal of Virology 68:6994–7000
    [Google Scholar]
  6. Donaldson Y. K., Bell J. E., Holmes E. C., Hughes E. S., Brown H. K., Simmonds P. 1994; In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop. Journal of Virology 68:5991–6005
    [Google Scholar]
  7. Fouts T. R., Binley J. M., Trkola A., Robinson J. E., Moore J. P. 1997; Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with the antibody binding to the oligomeric form of the envelope glycoprotein complex. Journal of Virology 71:2779–2785
    [Google Scholar]
  8. Groenink M., Fouchier R. A. M., Broersen S., Baker C. H., Koot M., Van’t-Wout A. B., Huisman H. G., Miedema F., Tersmette M., Schuitemaker H. 1993; Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260:1513–1516
    [Google Scholar]
  9. Hughes E. S., Bell J. E., Simmonds P. 1997; Investigation of the dynamics of the spread of human immunodeficiency virus to brain and other tissues by evolutionary analysis of sequences from the p17gag and env genes. Journal of Virology 71:1272–1280
    [Google Scholar]
  10. Javaherian K., Lanlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D., Matthews T. J. 1989; Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proceedings of the National Academy of Sciences, USA 86:6768–6772
    [Google Scholar]
  11. Mascola J. R., Snyder S. W., Weislow O. S., Belay S. M., Belshe R. B., Schwartz D. H., Clements M. L., Dolin R., Graham B. S., Gorse G. J., Keefer M. C., McElrath M. J., Walker M. C., Wagner K. F., McNeil J. G., McCutchan F. E., Burke D. S. NIAID AIDS Vaccine Evaluation Group 1996; Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. Journal of Infectious Diseases 173:340–348
    [Google Scholar]
  12. Moore J. P. 1992; MRC ADP reagent catalogue. Medical Research Council (London)
    [Google Scholar]
  13. Moore J. P., Ho D. D. 1995; HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T-cells. AIDS 9:S117–S136
    [Google Scholar]
  14. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. III Burton D. R., Ho D. D. 1995; Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of Virology 69:101–109
    [Google Scholar]
  15. Moore J. P., Cao Y., Leu J., Qin L., Korber B., Ho D. D. 1996; Inter- and intraclade neutralization of human immunodeficiency virus type 1 : genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of Virology 70:427–444
    [Google Scholar]
  16. Sawyer L. S. W., Wrin M. T., Crawford-Miksza L., Potts B., Wu Y., Weber P. A., Alfonso R. D., Hanson C. V. 1994; Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. Journal of Virology 68:1342–1349
    [Google Scholar]
  17. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. 1995; Replicative function and neutralizing sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. Journal of Virology 69:4413–4422
    [Google Scholar]
  18. Trkola A., Dragic T., Arthos J., Binley J. M., Olson W. C., Allaway G. P., Cheng-Mayer C., Robinson J., Maddon P. J., Moore J. P. 1996; CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184–187
    [Google Scholar]
  19. VanCott T. C., Bethke F. R., Burke D. S., Redfield R. R., Birx D. L. 1995a; Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. Journal of Immunology 155:4100–4110
    [Google Scholar]
  20. VanCott T. C., Polonis V. R., Loomis L. D., Michael N. L., Nara P. L., Birx D. L. 1995b; Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Research and Human Retroviruses 11:1379–1391
    [Google Scholar]
  21. Wang N., Zhu T., Ho D. D. 1995; Sequence diversity ofV1 and V2 domains of gp120 from human immunodeficiency virus type 1 : lack of correlation with viral phenotype. Journal of Virology 69:2708–2715
    [Google Scholar]
  22. Weber J., Fenyö E.-M., Beddows S., Kaleebu P., Björndal Å. The WHO Network for HIV Isolation & Characterization 1996; Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. Journal of Virology 70:7827–7832
    [Google Scholar]
  23. Wrin T., Loh T. P., Vennari J. C., Schuitemaker H., Nunberg J. H. 1995; Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. Journal of Virology 69:39–48
    [Google Scholar]
  24. Wu L., Gerard N. P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A. A., Desjardin E., Newman W., Gerard C., Sodroski J. 1996; CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179–183
    [Google Scholar]
  25. Zwart G., Back N. K. T., Ramautarsing C., Valk M., Van Der Hoek L., Goudsmit J. 1994; Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. AIDS Research and Human Retroviruses 10:245–251
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-79-1-77
Loading
/content/journal/jgv/10.1099/0022-1317-79-1-77
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error